Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Campbell, I. W
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Durable glycaemia — the promised land

Ian W Campbell

Diabetes Centre, Victoria Hospital, Hayfield Road, Kirkcaldy, Fife KY2 5AH, Scotland, UK, Jackie.Wallace{at}faht.scot.nhs.uk

Patients with type 2 diabetes experience progressive loss of glycaemic control and require intensification of glucose-lowering therapies. Durable glycaemic control has been shown to reduce microvascular and macrovascular complications in patients with type 1 diabetes or type 2 diabetes. The range of available glucose-lowering agents has been expanded with the addition of the thiazolidinediones (TZDs) pioglitazone androsiglitazone and, more recently, dipeptidyl peptidase-4 inhibitors and the glucagon-like peptide-1 analogue exenatide. In clinical trials, the TZDs have provided sustained glycaemic control, both in monotherapy and in combination with metformin and sulphonylureas. Pioglitazone has also been associated with improvements in the long-term cardiovascular morbidity and mortality of patients with type 2 diabetes. Br J Diabetes Vasc Dis 2009;9:53—63

Key Words: cardiovascular outcomes • pioglitazone • sustained glucose control • type 2 diabetes

References

  • Home P. Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes. Curr Med Res Opin 2005;21:989-98.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Selvin E., Marinopoulos S., Berkenblit G. et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141:421-31.[Abstract/Free Full Text]
  • Stettler C., Allemann S., Jüni P. et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 2006;152:27-38.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405-12.[Abstract/Free Full Text]
  • Ohkubo Y., Kishikawa H., Araki E. et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53.[Abstract/Free Full Text]
  • Fox KM, Gerber RA, Bolinder B. et al. Prevalence of inadequate glycaemic control among patients with type 2 diabetes in the United Kingdom general practice research database: a series of retrospective analyses of data from 1998 through 2002. Clin Ther 2006;28:388-95.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nichols GA, Alexander CM, Girman CJ et al. Treatment escalation and rise in HbA1c following successful initial metformin therapy. Diabetes Care 2006;29:504-9.[Abstract/Free Full Text]
  • Turner RC, Cull CA, Frighi V. et al. Glycaemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement of multiple therapies (UKPDS 49). JAMA 1999;281:2005-12.[Abstract/Free Full Text]
  • Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20.[CrossRef][Medline] [Order article via Infotrieve]
  • Esper RJ, Vilarino JO, Machado RA et al. Endothelial dysfunction in normal and abnormal glucose metabolism. Adv Cardiol 2008;45:17-43.[Web of Science][Medline] [Order article via Infotrieve]
  • Robertson RP, Harmon J., Tran PO et al. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003;52:581-7.[Abstract/Free Full Text]
  • Cleary PA, Orchard TJ, Genuth S. et al. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes 2006;55:3556-65.[Abstract/Free Full Text]
  • Writing Team for the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the micro-vascular complications of type 1 diabetes mellitus. JAMA 2002;287:2563-9.
  • UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Stratton IM, Holman RR Is the cardioprotective effect of metformin in type 2 diabetes dose dependent [Abstract]? Diabetes 2003; 52(suppl 1):A167-8.
  • Holman RR, Paul SK, Bethel MA et al.10-Year follow-up of intensive glucose control in type 2 Diabetes. UKPDS 80. N Engl J Med 2008;359(15):1565-76.[Abstract/Free Full Text]
  • Schellhase KG, Koepsell TD, Weiss NS Glycemic control and the risk of multiple microvascular diabetic complications. Fam Med 2005;37:125-30.[Web of Science][Medline] [Order article via Infotrieve]
  • ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007;99(12A):21i-33i.[Medline] [Order article via Infotrieve]
  • Karalliedde J., Gnudi L. ACCORD and ADVANCE: a tale of two studies on the merits of glycaemic control in type 2 diabetic patients. Nephrol Dial Transplant 2008;23:1796-8.[Free Full Text]
  • Tan M., Urquhart R., Baksi A. et al. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care 2005;28:544-50.[Abstract/Free Full Text]
  • Mazzone T., Meyer PM, Feinstein SB et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296:2572-81.[Abstract/Free Full Text]
  • Nissen SE, Nicholls SJ, Wolski K. et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561-73.[Abstract/Free Full Text]
  • Kahn SE, Heffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.[Abstract/Free Full Text]
  • Hanefeld M., Pfützner A., Forst T., Lübben G. Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study. Curr Med Res Opin 2006;22:1211-5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Schernthaner G., Matthews DR, Charbonnel B. et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004;89:6068-76.[Abstract/Free Full Text]
  • Yamanouchi T., Sakai T., Igarashi K. et al. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabet Med 2005;22:980-5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Perriello G., Pampanelli S., Di Pietro C. et al. Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with type 2 diabetes. Diabet Med 2006;23:246-52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Tan M., Johns D., Gonzalez Galvez G. et al. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, parallel-group trial. Clin Ther 2004;26:680-93.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Tan M., Johns D., Strand J. et al. Sustained effects of pioglitazone vs glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with type 2 diabetes. Diabet Med 2004;21:859-66.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hanefeld M., Patwardhan R., Jones NP et al. A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes. Nutr Metab Cardiovasc Dis 2007; 17:13-23.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Charbonnel B., Schernthaner G., Brunetti P. et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005;48:1093-1104.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Derosa G., D'Angelo A., Ragonesi PD et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006;31:375-83.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Matthews DR, Charbonnel BH, Hanefeld M. et al. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev 2005;21:167-74.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Derosa G., Cicero AF, Gaddi A. et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004; 26:744-54.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hanefeld M., Charbonnel BH, Brunetti P. et al. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004;27:141-7.[Abstract/Free Full Text]
  • Derosa G., Gaddi AV, Ciccarelli L. et al. Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial. J Int Med Res 2005;33:284-94.[Web of Science][Medline] [Order article via Infotrieve]
  • Rajagopalan R., Xu Y., Abadesa M. et al. The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials. Am J Geriatr Pharmacother 2006;4:123-33.[CrossRef][Medline] [Order article via Infotrieve]
  • Spanheimer R., Kupfer S., Perez A. et al. The effects of pioglitazone vs glyburide on glycemic control in patients with type 2 diabetes in a 3-year randomized double-blind trial. Diabetes 2006;55(suppl 1): A74-5.
  • Data on file: Efficacy and safety study of pioglitazone and metformin combination therapy and treating type 2 diabetes. Clinical trial identifier NCT00727857. Takeda Global Research & Development Center, Inc.
  • Charbonnel B., Dormandy J., Erdmann E. et al. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 2004;27:1647-53.[Abstract/Free Full Text]
  • Erdmann E., Dormandy J., Wilcox R. et al. PROactive 07: Pioglitazone in the treatment of type 2 diabetes: results of the PROactive study. Vasc Health Clin Risk Management 2007;3:355-70.
  • Chalmers J., Hunter JE, Robertson SJ et al. Effects of early use of pioglitazone in combination with metformin in patients with newly diagnosed type 2 diabetes. Curr Med Res Opin 2007;23:1775-81.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Schweizer A., Couturier A., Foley JE et al. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naive patients with type 2 diabetes. Diabet Med 2007;24:955-61.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Scherbaum WA, Schweizer A., Mari A. et al. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008, Mar 18: Epub ahead of print.
  • Nauck MA, Meininger G., Sheng D. et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rydén L., Standl E., Bartnik M. et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136.[Free Full Text]
  • Dormandy JA, Charbonnel B., Eckland EJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes: a randomized trial of pioglitazone. The PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events). Lancet 2005;366:1279-89.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lincoff AM, Wolski K., Nicholls SJ et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a metaanalysis of randomized trials. JAMA 2007;298:1180-8.[Abstract/Free Full Text]
  • Home PD, Pocock SJ, Beck-Nielsen H. et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007;357:28-38.[Abstract/Free Full Text]
  • Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.[Abstract/Free Full Text]
  • Rosen CJ The rosiglitazone story - lessons from an FDA Advisory Committee Meeting. N Engl J Med 2007;357:844-6.[Free Full Text]
  • Singh S., Loke YK, Furberg CD Long-term risk of cardiovascular events with rosiglitazone: a metaanalysis. JAMA 2007;298:1189-95.[Abstract/Free Full Text]
  • European Medicines Agency Press Office. Doc. Ref. EMEA/42232/2008. Downloaded from http://www.emea.europa.eu/pressoffice/chmp.htm (Accessed 4 October 2008).

The British Journal of Diabetes & Vascular Disease, Vol. 9, No. 2, 53-63 (2009)
DOI: 10.1177/1474651408100470
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Campbell, I. W
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?